Opinion|Videos|February 12, 2025
BOND-003 Trial and Cretostimogene for Treatment of NMIBC
Author(s)Mark D. Tyson, MD, MPH, Gary D. Steinberg, MD
Panelists discuss how cretostimogene grenadenorepvec is an intravesical oncolytic virus therapy targeting BCG-unresponsive bladder cancer through selective replication in tumor cells and immune stimulation via granulocyte-macrophage colony-stimulating factor expression.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What is cretostimogene grenadenorepvec? Please describe its mechanism of action.
- Discuss the phase 3 BOND-003 clinical trial investigating the use of the intravesical immunotherapy cretostimogene grenadenorepvec in patients with high-risk, BCG-unresponsive disease that was recently presented at the Society of Urologic Oncology 2024.
- What are your impressions of the BOND-003 data?
Advertisement
Related to this article
One year following the approval of the gemcitabine intravesical system, Joseph Jacob, MD, reflects on the expanding treatment landscape in BCG-unresponsive NMIBC.
The PDUFA target action date is in the fourth quarter of 2026.
Sandip Prasad, MD, discusses patient selection for chemoablation in recurrent LG-IR-NMIBC and considerations when counseling patients about a nonsurgical approach.
Enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) showed the strongest EFS, OS, and pCR associations among neoadjuvant MIBC strategies in a network meta-analysis, although perioperative design limits attribution.
Sandip Prasad, MD, MPhil, discusses the evolving role of chemoablation in recurrent low-grade, intermediate-risk NMIBC, including patient selection and treatment considerations.
Eugene Cone, MD, discusses recombinant BCG for NMIBC, including ongoing clinical evaluation and its potential to address ongoing BCG supply challenges.
A decision is expected by the fourth quarter of 2026.
Eugene Cone, MD, discusses SWOG S1602 findings comparing Tokyo-172 and TICE BCG and the potential role of alternative BCG strains in NMIBC
Advertisement
Advertisement
Trending on Urology Times
1
Pivotal trial launches of GRPR-targeted PET imaging agent in prostate cancer
2
One year of Inlexzo: Evolving care in BCG-unresponsive NMIBC
3
SBRT, prostatectomy show comparable long-term disease control in PACE-A trial
4
PSMA PET Radiotracers and Access Barriers in Prostate Cancer
5